Lola Luo

FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation

Kelly J. Norsworthy, Lola Luo, Vicky Hsu et al. · Clinical Cancer Research · 2019 · 133 citations

Differentiation Syndrome, Mixed-phenotype Acute Leukemia, Pharmacotherapy +16

FDA Approval Summary: Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease

Donna Przepiorka, Lola Luo, Sriram Subramaniam et al. · The Oncologist · 2019 · 129 citations · Full text

Transplantation Medicine, Pediatric Patients 12, Surgery +17

FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy

Vishal Bhatnagar, Nicole Gormley, Lola Luo et al. · The Oncologist · 2017 · 77 citations · Full text

FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim-Chester Disease with the <i>BRAF</i>V600 Mutation

Patricia O’Neal, Virginia E. Kwitkowski, Lola Luo et al. · The Oncologist · 2018 · 76 citations · Full text

Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer

Dickran Kazandjian, Gideon M. Blumenthal, Lola Luo et al. · The Oncologist · 2016 · 74 citations · Full text